Navigation Links
Bionovo's Drug Candidate for Menopausal Symptoms Shows Effect on Neural Pathways Related to Temperature Regulation
Date:6/16/2008

- Results Presented at Endocrine Society 90th Annual Meeting -

SAN FRANCISCO and EMERYVILLE, Calif., June 16 /PRNewswire-FirstCall/ -- Bionovo Inc. (Nasdaq: BNVI) today announced results from in vitro studies in neurons of its drug candidate, MF101. The data were presented at the Endocrine Society 90th Annual Meeting. Bionovo showed that, in neurons differentiated from mouse stem cells and expressing native estrogen receptors, MF101, an estrogen receptor beta selective modulator, regulated calcium levels, which are related to temperature regulation.

"Menopausal hot flashes occur in approximately 80% of menopausal women," said Dr. Dale Leitman, from the Department of Obstetrics, Gynecology and Reproductive Sciences at the University of California, San Francisco. "It has long been known that estrogens reduce hot flashes and non-selective SERMs cause hot flashes. However, there have not been appropriate cell-based models to screen estrogens for effects on neurons. This study demonstrated that changes in calcium levels in neurons, an important biochemical pathway to temperature regulation, are mediated selectively by the activation of estrogen receptor beta. MF101 demonstrated this selective regulation."

The study was conducted by investigators at The Center for Reproductive Sciences in the Department of Obstetrics, Gynecology and Reproductive Sciences at the University of California, San Francisco in collaboration with scientists at Bionovo.

"Although estrogens are very effective in the treatment of menopausal hot flashes, they have been associated with many serious health risks, such as breast and uterine cancer," said Isaac Cohen, Bionovo's chairman and chief executive officer. "In a Phase 2 clinical trial, M
'/>"/>

SOURCE Bionovo Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
3. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
4. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
5. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
6. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
7. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
8. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
9. Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501
10. Survival Data for Avicenas Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium on ALS/MND
11. Leading AIDS Groups Turn Up The Heat on 08 Presidential Candidates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... Israel , June 19, 2013 ... a phase I study in volunteers, and preliminary results ... of ND0612, were presented at the 2013 International Congress ... proprietary levodopa/carbidopa liquid drug formula under development for continuous ... maintain constant levodopa plasma concentrations. ND0612 has ...
(Date:6/19/2013)...   Life Technologies Corporation (NASDAQ: ... Suzhou Ribo Life Sciences (Ribo) the exclusive rights ... China using Life,s Invivofectamine® Rx ... in combination with Invivofectamine® Rx to create a ... high unmet medical need in the Chinese healthcare ...
(Date:6/19/2013)... Juni 2013 Specialty Coating ... Entwicklung von SCS microRESIST™, einer antimikrobiellen ... Beschichtung mit Parylene gelungen ist. SCS ... Parylene mit antimikrobiellen Eigenschaften und erlaubt ... auf beschichteten medizinischen Geräten. ...
Breaking Medicine Technology:NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 3NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 4NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 5NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 6Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 2Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 3Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 4Specialty Coating Systems gibt die Einführung einer neuen antimikrobiellen Parylene-Technologie bekannt 2
... TARRYTOWN, N.Y. and BERLIN, April 8, 2011 ... and Bayer HealthCare today announced that they have initiated ... the efficacy and safety of VEGF Trap-Eye (aflibercept ophthalmic ... certain eye diseases, in the treatment of Diabetic Macular ...
... Texas, April 7, 2011 Assured Pharmacy (APHY: pinksheets), ... more than 3,000 sufferers of chronic pain, has filed ... to effect a 1-for-180 reverse stock split of the ... reverse stock split in the number of issued and ...
Cached Medicine Technology:Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema 2Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema 3Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema 4Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema 5Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema 6Assured Pharmacy Announces Reverse Stock Split 2Assured Pharmacy Announces Reverse Stock Split 3
(Date:6/19/2013)... CCA , America's leader in partnership corrections, ... President, Health Services, effective June 8, 2013. Dr. ... CCA. He will replace the retiring Herb Spiwak. ... lead CCA's dedicated team of health care professionals. ... our partners as we provide effective care to persons ...
(Date:6/19/2013)... Chrysler made news recently when it refused ... million Jeeps. The Jeep models in question are the 1993-2004 ... to the NHTSA are vulnerable to fire and explosion in ... are rear-mounted and have been alleged to catch fire or ... Cherokee with 32 rear-end crashes, which resulted in 44 deaths ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 According to a ... Surviving Weekend Sunburn,” it is not uncommon for a person ... summer months. A person is likely to forget to reapply ... which is both dry and itchy. When this occurs, it ... to goo.gl/gDyjP). , “Most people do not realize that milk ...
(Date:6/19/2013)... online edition of the journal Nature , a ... California, San Diego School of Medicine visually monitored the ... occurs in zebrafish after cardiac ventricular injury. Their ... heart are more plastic, or capable of transformation into ... the research reveals a novel potential source of cells ...
(Date:6/19/2013)... Spanish . ... goes by the name of the 10/90 gap: only 10 ... that accounted for 90 per cent of the global disease ... for Neglected Diseases initiative (DNDi) came into being in 2003. ... granted the BBVA Foundation Frontiers of Knowledge Award in the ...
Breaking Medicine News(10 mins):Health News:CCA Names Dr. John Baxter Vice President, Health Services 2Health News:Zinda & Davis PLLC: Why the Chrysler Recall Refusal Matters And May Set a Dangerous Precedent 2Health News:Zinda & Davis PLLC: Why the Chrysler Recall Refusal Matters And May Set a Dangerous Precedent 3Health News:Skin Care – How to treat Sunburn 2Health News:Fate of the heart: Researchers track cellular events leading to cardiac regeneration 2Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 2Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 3Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 4Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 5
... French . , Montreal, March 11, 2009 ... influence of cannabis (DUIC) and engage in reckless driving, according ... the journal Accident Analysis and Prevention , men who ... consider taking the wheel after consuming cannabis more often than ...
... 11 On Friday, March 6, 2009, Coast ... Justice, the FBI, the FDA, and the Commonwealth of Virginia ... Independent Review Board discovered that a protocol submitted for review ... of Clifton, Virginia, was fraudulent in violation of federal and ...
... most progressive benefit management firms, today announced a strategic partnership with ... will enable CBCA to provide an unparalleled suite of proven care ... ... OH (Vocus) March 11, 2009 -- CBCA Administrators, Inc. (CBCA), one ...
... LOS ANGELES, March 11 MMR Information ... through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. ... Records ("PHRs") ( www.mymedicalrecords.com ) and electronic ... ), announced that it has selected Gene ...
... March 11 The U.S. Agency for ... in Southern Africa launched a new program to reduce ... and Mpumalanga Provinces. The three-year, $5.1 million project is ... Relief (PEPFAR), and administered by USAID . A ...
... researchers wanted to know whether an increased CO2 ... therefore examined freshwater micro-algae: small, floating and mostly ... tanks called limnotrons. These were aerated with ordinary ... of CO2. The researchers then examined the ratio ...
Cached Medicine News:Health News:Study finds cannabis use, dangerous driving behaviors interrelated 2Health News:Clinical Trial Fraud Exposed by Coast IRB 2Health News:CBCA Administrators, Inc. Announces Strategic Partnership with KePRO 2Health News:CBCA Administrators, Inc. Announces Strategic Partnership with KePRO 3Health News:MMR Information Systems, Inc. Taps Health Information Technology Veteran Gene Barduson 2Health News:MMR Information Systems, Inc. Taps Health Information Technology Veteran Gene Barduson 3Health News:MMR Information Systems, Inc. Taps Health Information Technology Veteran Gene Barduson 4Health News:MMR Information Systems, Inc. Taps Health Information Technology Veteran Gene Barduson 5Health News:USAID and IOM Announce HIV Prevention and Care for Farm Workers 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: